Interrogating circulating immune cell methylome differences across the TB disease spectrum (#304)
David Vincent L Romero
1
2
,
Abhimanyu Abhimanyu
3
,
Dylan Sheerin
1
2
,
Jovana Maksimovic
4
5
,
Robert J Wilkinson
3
6
7
,
Hanif Esmail
3
8
9
,
Belinda Phipson
1
,
Quentin Gouil
1
,
Matthew E Ritchie
1
,
Anna K Coussens
1
2
3
- Walter and Eliza Hall Institute for Medical Research, Parkville, VIC, Australia
- Department of Medical Biology, University of Melbourne, Melbourne, Vic, Australia
- Department of Infectious Diseases, Wellcome Centre for Infectious Diseases Research in Africa, Cape Town, Western Cape, South Africa
- Computational Biology Program, Peter MacCallum Cancer Centre, Melbourne, Vic, Australia
- Department of Oncology, Peter MacCallum Cancer Centre, Melbourne, Vic, Australia
- Infectious Diseases, The Francis Crick Institute, London, England
- Department of Infectious Diseases, Imperial College London, London, United Kingdom
- Medical Research Council Clinical Trials, Univerity College London, London, United Kingdom
- WHO Collaborating Centre for Tuberculosis Research and Innovation, Institute for Global Health, London, United Kingdom
Publish consent withheld
- Trauer, J.M., et al., Risk of Active Tuberculosis in the Five Years Following Infection . . . 15%? Chest, 2016. 149(2): p. 516-525.
- DiNardo, A.R., et al., DNA hypermethylation during tuberculosis dampens host immune responsiveness. J. Clin. Invest., 2020. 130(6): p. 3113-3123.
- Chen, Y.C., et al., Aberrant Toll-like receptor 2 promoter methylation in blood cells from patients with pulmonary tuberculosis. J Infect, 2014. 69(6): p. 546-57.